![]() | Medical News |
![]() | Articles |
![]() | Events |
![]() | Guidelines |
![]() | Videos Library |
![]() | Diseases |
Follow us : | ![]() |
![]() |
![]() |
![]() |
![]() |
-
Doctors (525026):
Luai Al Bakour -
Pharmacies (142854):
El Temamy Pharmacy -
Factories (9502):
Akoni Hijyen Teknolojileri Sanayi ve Dış Ticaret LTD. ŞTİ -
Laboratories (19243):
Britton Chance Center for Biomedical Photonics -
Hospital (68158):
City Hospital -
Agencies (6416):
Arabian Trade Center - ATC -
Medical Facility (32206):
Legality International. (Pvt.) Ltd.
Regla Ph
Main
You must sign in to use this servcieFeedback - Please use the form below to send your query or comment
You must sign in to use this servcie
Info
Indications: For the relief of hyperacidity and flatulence associated with heartburn, gastritis and acid indigestion, and as adjunctive treatment in peptic ulcers. |
|||
Contraindications: Sensitivity to any of the ingredients; Impaired renal function. |
|||
Adverse reactions: Gastrointestinal: Constipation; diarrhea; nausea; vomiting; intestinal obstruction. |
|||
Interactions: Oral tetracyclines, digoxin, oral iron preparations, anticholinergic drugs, barbiturates, quinines, quinidine, warfarin, vitamins, H2-receptor antagonists, oral isoniazid, sucralfate, sodium fluoride, ketoconazole, phenytoin, phenothiazines and methenamine: Aluminium Mg.S may reduce the absorption of these agents. |
|||
Warnings: Low-phosphate diets: Aluminium hydroxide in patients with low-phosphate diets may lead to phosphate depletion accompanied by increased resorption and urinary excretion of calcium with the risk of osteomalacia. Chronic renal failure: Osteomalacia, and also encephalopathy and dementia, have occurred in patients with chronic renal failure who received relatively high doses of aluminium hydroxide as a phosphate-binding agent. Hypermagnesemia has occurred after the excessive use of magnesium-containing antacids and especially in renal insufficiency. Symptoms may include flushing of the skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, loss of tendon reflexes due to neuromuscular blockade, muscle weakness, respiratory depression, cardiac arrhythmias, coma, and cardiac arrest. |
|||
Form: ORAL SUSPENSION |
Dosage and Administration
You must sign in to use this servcieTechnical Description
You must sign in to use this servcieDr. Hani Najjar
Dr. Samer Al-Jneidy
Yaser Habrawi , F.R.C.S.Ed
Dr. Tahsin Martini
Dr. Talal Sabouni
Dr. Faisal Dibsi
Samir Moussa M.D.
Dr . Dirar Abboud